Recombinant Growth Hormone Therapy in Patients With Ischemic Cardiomyopathy
Circulation1999Vol. 99(1), pp. 18–21
Citations Over TimeTop 1% of 1999 papers
Abstract
The administration of rhGH for 3 months in patients with ischemic cardiomyopathy results in significant improvement in hemodynamics and clinical function. The attenuation of left ventricular remodeling persisted 3 months after discontinuation of treatment.
Related Papers
- → History of growth hormone therapy(2011)64 cited
- → The Effect of Human Growth Hormone on Growth of Patients With Hypopituitarism(1968)17 cited
- → Increased Availability of Human Growth Hormone: A Challenge for Health Economics(1988)2 cited
- → Clinical Experience with r-hGH (Natural Sequence)(1987)
- → Factors Affecting Growth Hormone Delivery Device Choice for Patients and Parents(2008)